Roman Badik, CEO of Enantis, the first biotechnology spin-off from Masaryk University in the Czech Republic, shares his vision of turning the company’s research breakthroughs into a self-sustaining business. Badik breaks down the business model of Enantis based on its proprietary protein stabilization platform and its lead compound FGF2-STAB with applications in stem cell culture, healthcare and cosmetics.
Regarding healthcare, we wish to keep the IP here, so the added value stays in the Czech Republic for as long as possible
